Walmsley Looks Safe For Now, But GSK Faces M&A Pressure
Strategy Debate Will Rumble On
Executive Summary
Moves by Elliott Advisors to split up GSK and unseat Emma Walmsley look unlikely to succeed, but have already created pressure for more deal-making.
You may also be interested in...
GSK Unveils Plans For Major Europe Biotech Cluster
The under-pressure drugs giant has something to cheer with plans for a new campus that could attract several world-class research organizations to its doorstep and bring a multi-million pound windfall from the sale of land.
GSK's Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion
Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10 years.
Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.